Behavioural effects of selective PDE4 inhibitors in relation to inhibition of catalytic activity and competition for [3H]rolipram binding.
Kapui
Z
Z
CHINOIN Pharm. and Chem. Works. Ltd., Budapest, Hungary.
Bence
J
J
Boronkay
E
E
Mikus
E
E
Urbán Szabó
K
K
Baranyi
A
A
Arányi
P
P
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism; D001549:Benzamides / Q000494:pharmacology; D001667:Binding, Competitive; D020134:Catalytic Domain / Q000187:drug effects; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; D010208:Papaverine / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D010276:Parasympatholytics / Q000378:metabolism / Q000494:pharmacology*; D010726:Phosphodiesterase Inhibitors / Q000378:metabolism / Q000494:pharmacology*; D011725:Pyridines / Q000494:pharmacology; D020889:Rolipram / Q000378:metabolism / Q000494:pharmacology*; D014316:Tritium
D001549:Benzamides; D010276:Parasympatholytics; D010726:Phosphodiesterase Inhibitors; D011725:Pyridines; D014316:Tritium; C005317:drotaverin; D010208:Papaverine; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; D020889:Rolipram; C087566:piclamilast